Interventions for valvular disease and heart failure

First dedicated transcatheter leaflet splitting device: the ShortCut device

EuroIntervention 2022;18:e428-e429. DOI: 10.4244/EIJ-D-22-00344

Didier Tchétché
Didier Tchétché1, MD; Susheel K. Kodali2, MD; Danny Dvir3, MD
1. Clinique Pasteur, Toulouse, France; 2. Columbia University Irving Medical Center, New York, NY, USA; 3. Shaare Zedek Medical Center, Jerusalem, Israel

Figure 1. The Pi-Cardia ShortCut device. The ShortCut procedure: A. PA positioning; B. SE activation. The yellow circle shows splitting of the bioprosthetic leaflet facing the left main coronary artery; C. splitting; and D. good coronary flow post-split and TAVR. The arrow points to patency of the left main coronary artery at the end of the procedure. PA: positioning arm; SE: splitting element; TAVR: transcatheter aortic valve replacement

Coronary obstruction is a life-threatening complication that occurs in 2.3% of patients undergoing transcatheter aortic valve replacement (TAVR) for degenerated bioprostheses1. During a valve-in-valve (ViV) procedure, the leaflets of the prior valve ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Changes in voice patterns for monitoring heart failure deterioration

Latest news